News

HOUSTON, Feb. 20, 2024 /PRNewswire/ — Iterion Therapeutics, an oncology-focused biopharmaceutical company developing small molecule inhibitors of Transducin beta-like protein 1 (TBL1), a downstream target in the Wnt/beta-catenin signaling pathway, announced today it is actively enrolling a Phase 1b/2a clinical trial of its lead molecule, tegavivint, in patients with advanced hepatocellular carcinoma (HCC) that have failed at least …

Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments Read More »

Iterion announces collaboration with Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute.

Iterion shares results from collaboration with Cancer Research UK (CRUK)

Results announced from dose escalation study of tegavivint in desmoid tumors.  

Iterion Therapeutics announces presentation of three posters involving research into tegavivint at the AACR 2022 Annual Meeting

Iterion initiates Phase 1 clinical trial to investigate tegavivint in a first-line combination study with osimertinib in previously untreated patients with metastatic epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer.

Children’s Oncology Group Pediatric Early Phase Clinical Trials Network, a National Cancer Institute-supported clinical trials group, sponsors first clinical study for tegavivint in the pediatric population

Iterion Therapeutics announces phase 1 clinical trial.

Iterion Therapeutics hires Jean Chang as Chief Operating Officer.  

Iterion Therapeutics confirms safety of tegavivint following completion of enrollment in phase 1/2a expansion study.